Joint Medicines Regulatory Procedure in the East African Community: Registration Timelines and Way Forward by Mashingia, Jane et al.
Purdue University 
Purdue e-Pubs 
BIRS Africa Technical Reports Biotechnology Innovation and Regulatory Science Center Global Community 
11-1-2021 
Joint Medicines Regulatory Procedure in the East African 
Community: Registration Timelines and Way Forward 
Jane Mashingia 
Purdue University, mashingiaj@eachq.org 
S Maboko 
Tanzania Medicines and Medical Devices Authority 
P I. Mbwiri 
Pharmacy and Poisons Board, Nairobi, Kenya 
A Okello 
National Drug Authority, Kampala, Uganda 
S I. Ahmada 
Zansibar Food and Drugs Authority, Zanzibar 
See next page for additional authors 
Follow this and additional works at: https://docs.lib.purdue.edu/birsafricatr 
Recommended Citation 
Mashingia, Jane; Maboko, S; Mbwiri, P I.; Okello, A; Ahmada, S I.; Barayandema, R; Tulba, R; Byomuhangi, 
E; Ekeocha, Z; Byrn, S; and Clase, K, "Joint Medicines Regulatory Procedure in the East African 
Community: Registration Timelines and Way Forward" (2021). BIRS Africa Technical Reports. Paper 3. 
http://dx.doi.org/10.5703/1288284317429 
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. 
Please contact epubs@purdue.edu for additional information. 
Authors 
Jane Mashingia, S Maboko, P I. Mbwiri, A Okello, S I. Ahmada, R Barayandema, R Tulba, E Byomuhangi, Z 
Ekeocha, S Byrn, and K Clase 




             
 
 
                






               
                
                
              
        
 
                    
                   
               
              
                  
                 
 
                
                 
                
      
 
            
    
          
  
                                                 
          
          
           
        
       
        
         
          
       
             
  
             
  
            
   
1
Joint Medicines Regulatory Procedure in the East African Community: Registration Timelines and Way
Forward
J. H. Mashingia1, S. Maboko2, P.I. Mbwiiri3, A. Okello4, S. I. Ahmada5, R.Barayandema6, R. Tulba7, E.
Byomuhangi8, Z. Ekeocha9, S. Byrn10, K. Clase11 
ABSTRACT
A review of the East African Community (EAC) joint regulatory review process was conducted, registration
timelines analyzed and key milestones, challenges and opportunities documented for the period of July 2015 to
January 2020. A total of 113 applications were submitted for joint scientific review. Among these, 109
applications were assessed, 57 were recommended for marketing authorisation, 52 applications had queries to
applicants and four applications were under review.
A total median approval time for all products ranged from 53 to 102 days. The maximum time taken by a
regulator to review the dossier was 391 days and the minimum time was 44 days. For applicants, the maximum
time to respond to queries was 927 days and the minimum time was nine days.
The total median time for granting marketing authorisation by the National Medicines Regulatory Authorities
(NMRA) decreased from 174 to 39 working days in 2015 and 2019 respectively. However, not all EAC NMRA
has granted marketing authorisation to all 57 products due to non-payment of applicable fees by applicants.
Long regulatory approval timelines were contributed by limited capacity for timely scientific review of dossier by
some NMRA, lack of online portal to share dossiersand assessment reports, delay in responding to queries by
applicants and deficiencies in dossier. The metric tool and register of medical products submitted for joint
scientific review had incomplete data.
Challenges were identified and actions recommended to ensure regional regulatory system optimization,
efficiency, transparency, sustainability and accountability. 
Keywords: Registration, assessment, timelines, harmonization, regulatory review, medicinal Products, marketing
authorization
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1. INTRODUCTION
Harmonization of pharmaceutical regulations and
cooperation at regional and continental level
contribute to increase availability of high-quality, safe
and effective medicines in developed and developing
countries (Pierre, 2014). Harmonization of
regulations involves establishing an effective
network of continental regional and national, or
regulatory authorities. The networks facilitate sharing
of scientific knowledge, best practices, skills and
appropriate use of limited resources to avoid
duplication of efforts, reduce cost to pharmaceutical
industry and promote innovation and development of
medicines for unmet medical needs (Ndomondo-
Sigondaet al, 2017). The networks are important
structures to build regulatory capacities and
capabilities, trust and confidence between National
Medicines Regulatory Authorities (NMRA).
Conceptualization of harmonization of medicines
regulatory frameworks in the East African
Community started in 2009 during a continental
meeting of Drug Regulatory Authorities (DRA) that
was convened to discuss issues surrounding
harmonization of drug regulatory requirements and
systems in the African continent. The meeting was
organized by African Union New Partnership for
African’s Development (AU-NEPAD Agency), under
auspices of African Union Pan African Parliament
(PAP), with support from the Bill and Melinda Gates
Foundation (BMGF). The East African Community
(EAC), with the main mandate of facilitating
integration and harmonization of legal, policy and
regulatory instruments, was better placed to
coordinate the initiative to address regulatory and
technical barriers on access to medicines, vaccines
and health technologies. EAC is a regional inter-
governmental organization of the six Partner States
Technical partners include WHO and Swiss Agency
for Therapeutic Products, while African Union
Development Agency (AUDA) plays a high level
advocacy role on medicines regulation
harmonization in the continent working with Regional
Economic Communities (REC) such as EAC,
Southern African Development Community (SADC)
and Economic Community of West African States
(ECOWAS), Partners (BMGF, UK-DFID, WB, USAID
and SDC) provide financial resources to AMRH Trust
Fund to support AMRH initiative in different RECs.
The programme has six objectives:
a) To implement an agreed common technical
document (CTD) for registration of
medicines in EAC Partner States;
namely: The Republic of Burundi, the Republic of
Kenya, the Republic of Uganda, the Republic of
Rwanda, Republic of South Sudan and United
Republic of Tanzania (www.eac.int). The six Partner
States have a unique framework for regional
cooperation, and integration in the health sector, as
stipulated in the EAC Treaty, Chapter 21, Article 118
(EAC, 2000). The East African Community
Medicines Regulatory Harmonization (EAC-MRH)
programme was launched by the EAC Council of
Ministers on 30th March 2012, with the goal of
establishing a standardized and harmonized
regulatory systems to ensure safe, efficacious,
quality and effective medicines for treatment of
priority diseases (S. EAC, 2010). The programme is
implemented by seven National Medicines
Regulatory Authorities (NMRA) and EAC Secretariat
is the coordinating body. The implementing agencies
include the Department of Pharmaceuticals and
Medical Laboratories (DPML) of Burundi, Pharmacy
and Poisons Board (PPB) of Kenya, National Drug
Authority (NDA) of Uganda, Drug and Food Control
Authority (DFCA) of South Sudan, Rwanda Food and
Drugs Authority (Rwanda FDA), Tanzania Medicines
and Medical Devices Authority (TMDA) and Zanzibar
Food and Drugs Agency (ZFDA) of the United
Republic of Tanzania. In addition, the African
Medicines Regulatory Harmonization Partners
(AMRH), namely the World Health Organization
(WHO), African Union Development Agency (AUDA),
formerly known as African Union New Partnership for
Africa’s Development (AU-NEPAD), the Bill and
Melinda Gates Foundation (BMGF), the World Bank
(WB), United Kingdom Department for International
Development (UK-DFID), Swiss Development
Corporation (SDC) and United States Agency for
International Development (USAID) provided support
to the initiative. 
b) To implement a common information
management system (IMS) for medicines
registration in each of the EAC Partner
States NMRA which are linked in all Partner
States and EAC Secretariat;
c) To implement a quality management system
in each of the EAC Partner States NMRA;
d) To build regional and national capacity to
implement medicines registration
harmonization in the EAC;
e) To create a platform for sharing information
on the harmonized medicines registration





        
      
       
 
       
        
     
     
    
     
      
    
    
     
      
      
      
  
       
    
    
     
      
       
        
     
      
 
       
    
      
      
        
      
 
       
      
  
      
  
       
 
           
       
     
      
       
        
      
      
      
       
     
      
       
         
       
       
        
        
      
         
      
      
      
      
        
           
        
         
         
          
      
      
       
         
        
         
          
     
      
       
         
       






f) To develop and implement a framework for
mutual recognition based on Chapter 21,
Article 118 of the East African Community
Treaty.
The initial phase of the EAC-MRH programme
(March 2012 - December 2017) focused on:
a) establishment of regional governance
structures to support implementation and
sustain the programme
b) development of harmonized technical
guidelines, procedures and tools for joint
registration (EAC Common Technical
Document-CTD) and joint good
manufacturing practices (GMP) inspections
c) establishment of a quality management
system in all EAC NMRA
d) institutional capacity building on regulatory
sciences
e) high level policy advocacy for establishment
of semi-autonomous National Medicines
Regulatory Authorities (BCG, 2017).
EAC Joint Regulatory Procedure
EAC joint medicines regulatory procedure involves
joint scientific evaluation of safety, efficacy and
quality of medicinal products and joint inspections of
pharmaceutical manufacturing facilities to assess
compliance to Good Manufacturing Practices (GMP)
standards.
The following procedures are undertaken under the
EAC joint regulatory review:
a) Evaluation of medical product dossiers;
b) Joint physical inspections of manufacturing
sites or desk review in line with EAC
Compendium of guidelines for GMP (EAC,
2018);
c) Joint inspections of clinical sites, if
applicable according to the Good Clinical
Practices (GCP);
d) Joint post-marketing surveillance and safety
reporting;
e) Enforcement of joint regulatory decisions by
NMRA.
For the purpose of this study, the focus was on joint
evaluation of medicinal product dossiers, which also
involves joint inspections of pharmaceutical
manufacturing facilities, depending on outcomes of
dossier evaluation. The study narrowed down on
analysis of registration timelines to evaluate if the
process demonstrated efficiency and could be
optimized to ensure predictability, consistency and
accountability. The terms “joint assessment” and
“registration” will be used interchangeably with joint
registration procedure or dossier evaluation.
Submission of Dossier in CTD Format
The EAC joint assessment and registration process
came to fruition in July 2015 after nine medicinal
product dossier applications were lodged for joint
evaluation and registration. The EAC procedure is
highlighted in Figure 1. The procedure begins with
submission of an application to TMDA, the lead
NMRA for Medicines registration (Step) The
medicinal product dossier should be in line with EAC
guidelines on submission of documentation for
registration of human medicinal products for
preparation of marketing authorization application in
the common technical document (CTD) (EAC,
2019a). Screening is conducted by the lead NMRA
(Step 2) and the lead NMRA for GMP will be notified
to verify GMP status and the applicant notified
whether the dossier is accepted or rejected within 14
days. If the dossier is complete, the application will
be assigned to 1st and 2nd assessor, as per EAC
standard operating procedure for joint assessment,
and scheduled for joint assessment. Dossier
assessment will be conducted within three months
following successful screening (Step 3, 3.1 & 4). The
evaluation of additional data will be conducted within
two months of receipt and a maximum of three
rounds of queries is permitted (Step 5, 5.1 & 5.2).
Following successful dossier evaluation and
compliance with Good Manufacturing Practices, the
experts will make recommendations to the EAC
Heads of NMRA and will recommend to the EAC
Secretariat to issue confirmation letter to the
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Figure 1. Infographic of EAC Joint Assessment Procedure
National administrative procedure to grant marketing
authorisation (MA) takes three months from the date
of joint acceptance. The respective EAC Partner
States NMRA will issue a certificate of MA, which
confirms the final registration outcome (Step 8).
Registered products shall be maintained in each
NMRAs list of registered products and EAC
Secretariat (Step 9). The EAC Partner States will then
monitor the safety and quality of the products in line
with the national policies and regulations. In addition,
EAC Compendium of Pharmacovigilance Guidelines
(EAC, 2019b) requires the applicant to ensure safety
of their products they place in the EAC market and in
this regard, the EAC NMRA will jointly monitor safety
of the products registered through the EAC-MRH
scheme using standardized tools and procedures.
According to the EAC joint assessment procedure,
scientific evaluation of dossiers by a regulator should
be carried within 181 working days. The applicant’s
response to queries is 180 working days. Once a
regional positive outcome of the assessment is
issued, alle EACNMRA are required to issue
marketing authorization within 90 working days
following a positive regional recommendation.
EAC Joint Good Manufacturing Practices
Inspections
Initiation of EAC Joint GMP inspection may occur
through three mechanisms:
a) A joint procedure in the framework of multiple
applications for marketing authorization to
more than one NMRA
(joint assessment and registration);
b) An official request from a manufacturer;
c) A joint interest of at least two EAC Partner
States NMRA.
The procedure for joint GMP inspections, as indicated
in Figure 2, requires an applicant to submit an
application including the Site Master File and
applicable fees to the lead NMRA for GMP, National
Drug Authority (NDA), Uganda and other NMRAs, as
per their fee guidance. Scheduling of joint inspections
will be done by the lead NMRA, while the maximum
number of inspectors per site is three, drawn from two
NMRAs. Communication of the inspection dates will
be done within 14 days by the lead NMRA. Site visit
and inspection will be conducted within 30 working
days from the day of scheduling. Communication of
the outcome of inspection will be within 42 working
days from the dates of inspection. Review of
Corrective and Preventive Actions (CAPA) and
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Scheduling in 14 Days 
Planning for Inspection 
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Inspection in 5 Days 
l 
Report Writing in 14 Days 





in 14 Days 
Communication to applicant 
in 5 Days 
5
Figure 2. EAC Joint GMP Inspection Procedure Flow Chart
The letter, which confirms the final inspection
outcome, will be communicated by the EAC
Secretariat. National approval will be granted within
three months from the date of joint acceptance; and
respective EAC NMRAs will issue a certificate, which
confirms the final inspection outcome. EAC NMRA will
maintain the list of inspected sites and continue to
monitor compliance to EAC GMP standards after
every three years.
To ensure timely availability of quality medicinal
products and effective medicines registration and
marketing authorization, it is important to have
timelines tracking the system to evaluate performance
of the system and ensure compliance to agreed
timelines. The EAC has developed a comprehensive
metric tool to track timelines for joint registration and
joint GMP inspections. The clock stop system is
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Metric Tools to Track Timelines of Joint
Assessment Procedure
The metric tool for joint registration procedure is an
Excel sheet which contains six sections as indicated
below:
(i) Section 1: Application Details
This section documents application number,
brand name, generic name, pharmaceutical
form, therapeutic class, type of product,
applicant name, manufacturer, date of
submission of dossier and date of notification
to the EAC expert working group (EWG) for
GMP.
(ii) Section 2: Screening Process (14 days)
This part covers the date of completion of the
screening, date when the outcome of
screening is communicated to applicant, date
of receipt of updated dossier, final outcome
(accepted/rejected) and date of
acceptance/rejection of dossier.
(iii) Section 3: Evaluation Process
First Cycle of Evaluation
• Date the first assessment is completed (21
days);
• Date second assessment completed (14
days);
• Date the assessment report is discussed and
finalized (seven days);
• Date recommendations are communicated to
applicants (14 days).
Second Cycle of Evaluation
(First Round of Queries)
• Date additional information is submitted by
applicant (180 days);
• Date first assessment of query response is
completed by first assessor (14 days);
• Date second assessment of query response
completed by second assessor (seven days);
• Date when query response assessment
report discussed and finalized at EAC (seven
days);
• Date when recommendation is
communicated to applicant (seven days).
Third Cycle of Evaluation
(Second Round of Queries)
• Date additional information is submitted by
applicant (120 days);
• Date when first assessment of query
response is completed by first assessor (14
days);
• Date when second assessment of query
response is completed by second assessor
(seven days);
• Date when query response assessment
report is discussed and finalized at EAC level
(seven days).
Fourth Cycle of Evaluation
(Third and Final Round of Queries)
• Date additional information is submitted by
applicant (120 days);
• Date when first assessment of query
response completed by first assessor (14
days);
• Date when second assessment of query
response completed by second assessor
(seven days);
(iv) Section 4: Final Recommendations
This section captures information on whether the
product has been accepted or rejected. It also
covers:
• Date when final recommendations are
reached;
• Date when final recommendations are
communicated to applicant.
(v) Section 5: NMRAs Implementation of
Regional Recommendations
This section contains the following:
• Date when EAC Secretariat communicates
final recommendations to all EAC NMRA
(14 days);
• Date when the product is granted marketing
authorization (MA) by each individual EAC
NMRA (90 days).
(vi) Section 6: Post Approval Process
The section document time period of
communication made to theEAC expert working
group (EWG) for pharmacovigilance (PV) and
post-market surveillance (PMS) following
approval for marketing authorization., This also




         
     
       
          
       
  
 
     
      
      
       
       
     
    
         
       
 
    
   
      
       
     
       
      
        
    
        
    
     
   
      
    
     
      
    
   
       
  
        
   
        
      
   
 
       
         
    
     
       
     
    
    
   
   
      
       
     
   
      
       
     
   
 
      
 
      
   
        
         
          
   
    
       
      
      
      
         
        
        
     
      
         
     
     
       
         
   
      
         
         
        
        
       
7
is withdrawn from the market, then it should be
documented in this section.
Metric Tool for EAC Joint GMP Inspections
The metric tool for EAC Joint GMP Inspections is an
Excel sheet which contains five sections as
highlighted below.
Section 1: Application Details
This section captures information on application
number, name of applicant, site(s) address(es),
contact person on site, category of medicines,
registration status of products and number of
production lines to be inspected.
Section 2: Screening Process
This part covers date of completion of screening (five




• Scheduling of inspections (14 days);
• Date of lead NMRA communicates to
applicant on Schedule of Inspection;
• Date Lead NMRA communicates to Partner
States on dates of joint inspections;
• Date the applicant confirms the inspection to
be conducted (30 days);
• Submission of names of inspectors by EAC
Partner States (seven days).
Section 4: Planning and Inspection
This section covers:
• Planning and preparation (30 days);
• Inspection (five days);
• Report writing (seven days);
The evaluation process is a step-by-step process and
the metric tool has been designed to document the
time period (working days) of each step using a clock
stop system.
Confidentiality of Manufacturers Data
Confidentiality of shared data is assured by
mechanisms applied by participating parties (EAC
NMRA). Participating NMRA create a written
commitment that “any information and documentation
provided to them by applicants will be treated as
confidential and access to this information will be
allowed only to persons involved in the joint
assessment and registration procedure”. The
• Peer-review monthly reviews (14 days);
• Recommendations communicated to
applicant (five days).
Section 5: Review of Corrective and Preventive
Action (CAPA)
• Date submission of CAPA is done by
applicant (90 days);
• Date review of CAPA concluded (14 days);
• Date recommendations are communicated to
applicant (five days);
Clock Stop System for EAC Joint Assessment
The clock watch system for EAC joint assessment and
registration is summarized below:
• First Cycle of Evaluation
o Clock Stop 1: The evaluation is
paused (first clock stop) while
the applicant prepares the
responses to EWG for
Medicines evaluation and
registration (MER).
• Second Cycle of Evaluation
o Clock Stop 2: The evaluation is
paused again for applicant to
address outstanding issues.
• Third Cycle of Evaluation
o Clock Stop 3: The evaluation is
paused for applicant to provide
clarifications on outstanding
issues.
• Fourth Cycle of Evaluation
• Final discussion and adoption of
scientific review opinion.
expertsare bound by confidentiality statement and
commitment as specified in Part 5 of the EAC
Compendium of Quality Management System
Technical Documents For Harmonization of
Medicines Regulation in the East Africa Community,
the EAC Code of Conduct for EAC Partner States
NMRA (EAC/TF-MED/QMS/FD/COM/N3R0).
Timelines for EAC Joint Assessment Procedure
The time spent by EAC experts to conduct scientific
evaluation is 181 working days and the time is
interrupted by three clock stops during which the
applicant prepares the answers to questions raised by




        
         
      
       
      
        
      
         
       
       
       
      
        
         
    
         
        
         
     
     
        
   
        
   
       
 
  
        
          
        
       
         
       
       
       
      
     
     
     
      
       
       
       
     
  
        
     
       
  
       
     
   
       
      
         
     
     
         
       
         
       
      
      
      
     
      
          
         
         
         
       
        
       
          
        
        
         
      
      
     
  
 
         
    
 
 
    
       
         
         
        
       
         
        
        
         
        
        
        
  
         
         
     
        
       
8
evaluation and registration (MER). The time for the
applicant to respond to queries is 180 working days
while national administrative procedures to grant
marketing authorisation is 90 working days. The
overall assessment of medicinal products usually
takes approximately a full calendar year (360 days).
Since commencement of joint assessment and
registration procedure in July 2015, a total of 113
applications have been submitted for joint scientific
review. Among these, 109 applications have been
assessed, 57 have been recommended for marketing
authorisation, 52 applications have queries to
applicants and 4 applications are under review.
Studies have been conducted in relation to the East
African Medicines Regulatory Harmonization
Programme (Hiiti et al., 2020; Jane et al., 2020;
Margareth et al., 2020). However, none focused on
analysis of the registration timelines for the EAC joint
evaluation procedure. This study therefore
wasconducted with the following objectives:
(i) To document stages of the EAC joint
regulatory review process;
(ii) To review the metric tool and analyse
registration timelines;
(iii) To identify key milestones, challenges and
opportunities.
Data collection template was developed to enable
structured documentation of all relevant information
extracted from the metric tool (Excel sheet) in a
summarized manner. The template contained
information on application number, pharmaceutical
form, therapeutic class and type of product, date of
submission of application, notification to EWG on
GMP, type of assessment (full or abridged), round of
assessment, date when final report was discussed
and completed, regulators time (working days),
applicant timelines (working days), final outcome
(accepted /rejected) and date when final
recommendation were communicated to the
applicant. Regulators and applicant timelines were
obtained by reviewing data in the metric tool for each
product from the date of submission, date of clock
start/stop and date of approval. Number of days were
counted for each evaluation step, as indicated in the
introduction section of the evaluation steps and
rounds of queries. Timelines for the applicant and
regulator were obtained considering clock start and
stop system and summed up to get the total number
of working days. Appendix 2 summarizes the findings
and registration timelines of each product. Based on
the metric tool and the EAC register of medicinal
products, the 57 medical products were
recommended for marketing authorisation hence they
formed study sampling frame.
2. METHODS
Information on the total number of applications and
approvals for the period of July 2015 to January 2020
was obtained from the register of medicinal products
submitted for joint evaluation and registration (TMDA,
2015). Review of the metric tools for joint evaluation
procedure and joint GMP inspections was done
(RTO's & Secretariat, 2018a; 2018b). Analysis of
regulatory approval times between July 2015 to
January 2020 for 57 medicinal products
recommended for registration was conducted.
Retrospective review of other program
documentations, such as guidelines, templates,
standard operating procedures (SOP’s) and reports,
was conducted. Documents were available at EAC
Secretariat and others were obtained from Tanzania
Medicines and Medical Devices Agency (TMDA) and
National Drug Authority (NDA).
Study Hypothesis
• There is a significant reduction in the
regulatory approval timelines between 2015
and 2020 for EAC joint assessment and
registration procedure;
• Long regulator timelines are associated with
the type of evaluation process.
Data Collection
Statistical Analysis
Study data was processed in Microsoft Excel to test
the hypotheses and examine
associationsbetweenvariables.
3.RESULTS AND DISCUSSION
Scientific evaluation of safety, quality and efficacy
data in the dossier was conducted by assessors from
the seven EAC NMRA. Two experts from each EAC
NMRA formed the EAC Expert Working Group (EWG)
for Medicines Evaluation and Registration (MER). The
primary mandate of this network of assessors was to
provide technical guidance in all matters related to
medicinal product registration to the Forum of Heads
of EAC NMRA. This arrangement was adopted by the
EAC Council of Ministers in September 2014, since
there was no regional regulatory body that is
mandated to oversee regulation of medicines in the
EAC region.
As indicated in Figure 1, once a dossier was
submitted and accepted, it was assigned to first and
second assessors. The assessors conducted
evaluation at the national level and shared reports




      
   
         
       
       
      
        
       
        
         






               
       
         
          
       
         
        
         
          
        
        
       
        
       
       
       
       
      
          
      
        
           
     
      
          
          
          
      
         
          
   
        
         
      
       
        
       
      
      
       
       





was reviewed and discussed during face-to-face and the lowest number was in 2018 (n = 5) , as
meetings with assessors. indicated in Appendix 1.
A total of 113 applications were submitted for EAC
joint scientific review. Among these, 109 applications
were assessed, 57 were recommended for marketing
authorisation, 52 applications had queries to
applicants and four applications were under review.
The highest number of products recommended for
marketing authorization was in the year 2016 (n=19)














2015 2016 2017 2018 2019 
Year 
Regulator Timelines Applicant Timelines 
There was a significantly long regulatory approval
timeline (1,052 working days) in 2016, as indicated in
Figure 3 above. The main reason was the delay of
manufacturers to respond to queries raised, which
took 927 working days, while the regulator’s time was
125 working days. A similar challenge was observed
by Ahonkhai et al. (2016) in which long regulatory
review period was due to delay to respond to queries
by sponsor. In addition, the quality product dossier
submitted had insufficient data, which led to more
rounds of queries and negatively impact review
period. The EAC assessors had an obligation to
ensure the products submitted for registration met
standards as stipulated in EAC guideline for
registration of human medicinal products. The trend
of timelines for regulators indicated a steady
improvement throughout the years. This was
contrary to the findings by Dansie et al. (2019), which
indicated hesitation of manufacturing companies to
use the EAC joint assessment procedure. The main
reason was due to the length of time to receive the
actual marketing authorization and unexpectedly
higher quality standards than national procedures.
For all 57 products, the longest time taken by a
regulator to review the dossier was 391 days in 2016
and the shortest time was 44 days in 2019. For
manufacturers (applicant), the longest time to
respond to queries was 927 days (2015) and the
shortest time was 9 days in 2018 (Figure 3 &
Appendix 2).
For regulators, the root cause of long review
timelines was mainly due to lack of an integrated
information management system portal to support
timely sharing of dossiers and assessment reports.
In addition, the region had NMRA with different
capacities and capabilities of assessors to conduct
timely scientific reviews of medicinal product
dossiers of different product categories. However,
the EAC-MRH program continued to provide a
greater opportunity for capacity building across the









      
         
   
    
       
        
     
      
       
      
      
        
       
    
     
        
       
        
       
         
       
       
      
      
      
       
       
      
       
       
      
      
     
      
       
       
       
         
         
         
         
       
        
           
         
            
      
           
         
        
          
        
         
          
       




Figure 4. Therapeutic Category of Products Submitted for EAC Joint Assessment Procedure 
Treatment of Male Impotence 
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Regulator Timelines Applicant Timelines 
Therapeutic categories of products submitted for
joint evaluation process for the past five years were
mainly antineoplastic/biologicals, antidiabetics,
monoclonal antibodies, antimicrobials and
antihypertensives as indicated in Figure 4. The
scope of products for consideration under the EAC
joint assessment procedure included medicines,
biotherapeutics and biosimilars. The priority was
given to medicines to manage maternal, neonatal
and children’s health conditions, HIV, malaria,
tuberculosis and neurological disorders. In addition,
the EAC Expression of Interest have listed category
of products for management of neglected diseases
such as leishmaniasis, pneumocystosis,
toxoplasmosis, filariasis and strongyloidiasis (EWG
& Registration, 2020). Apart from the listed products,
the EAC routinely conducted mapping of common
applications submitted in at least two EAC Partner
States NMRAs and requested the applicant to
consent to participate in the joint review process.
A joint assessment procedure involved full and
abridged evaluations. An abridged procedure was for
medicinal products already approved by stringent
regulatory authorities and the WHO prequalification
program. For this procedure, the assessors
employed a risk-based approach in the evaluation
process and review of the quality information
summary of the finished pharmaceutical product
(QIS-SRA) submitted by the applicant. The reviewer
focused on the main aspects of Active
Pharmaceutical Ingredient (API) quality and stability.
For finished pharmaceutical product, the assessor
reviewed specifications, labelling and the
manufacturing process. For any variations (post
approval changes) to the products, the EAC
guideline on variation to a registered pharmaceutical
product or vaccine would be applicable.
Full evaluation involved review of all data related to
quality, safety and efficacy of the drug product. For
this study, data were analysed according to the type
of evaluation to discover if this variable would have
an impact on regulator timelines and determine
whether the hypothesis was true. As indicated in
Figure 5 below and Table 2 (Appendix 2), for the year
2019, full evaluations of product 040, 041, 042, 043
and 044 took a period of 166, 63, 63 and 85 working
days respectively; while abridged assessment of
product 045, 046, 047, 048 and 049 in the same year
took 222, 222, 222, 222 and 229 working days
respectively. In addition, in the year 2015, abridged
evaluation of product 001, 002, 003 and 004 took 53
working days each, while full evaluations of product
005, 006, and 007 took 125 working days each.
Based on the findings for the year 2015, 2016, 2018
and 2019, there was no correlation between
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Figure 5. Regulator’s Timelines Vs Type of Assessment Method for a Period of 2015 to 2019
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For the year 2019, abridged assessment took longer submitted for the joint review process as indicated in
than 181 days, as per the standard operating Appendix 2. Incomplete data in the metric tool and
procedure for joint assessment; while full other records should be addressed by the
assessment was less than 181 days for the five programme implementers so that future studies’
products mentioned above. For year 2015, both findings can represent the real situation.




           
         
         
        
       
        
     
     
      
      
        
     
   
          
 
        
     
    
          
      
     
         
          
       
         
          
          
         
       
        




          
 
 
       
      
          
        
         
      
        
       
         
           
12
products ranged from 53 days in 2015 to 102 days in
2019. There was a significant increase in the total
median approval time (476 working days) in 2016, as
indicated in Figure 6. Long median time was
contributed due to the following reasons:
a) the dossier submitted by the applicant did
not have bioequivalence data to
demonstrate that a generic product
submitted for registration is bioequivalent to
its reference or originator product;
b) the package of products submitted did not
meet EAC Common Technical Document
(CTD) requirements;
c) there was a delay in response to queries by
applicants
d) there was a delay in submission of
assessment reports by assessors
e) stringency of regulators.
Deficiencies in the dossier were also observed by a
study conducted by the WHO prequalification
program (Wondiyfraw et al., 2012).
During the same period (2016), the median time for
an applicant was 187 days while median time for a
regulator was 289 days. The findings further
indicated a decrease in total median time from year
2017 to 2019, as indicated in Figure 6. The median
time for a regulator decreased from 169 days to 102
days and manufacturers ranged from 88 days to zero
days. This showed improvements in the processes
and high commitment by all stakeholders involved in
the joint assessment procedure, which led to
Figure 6. Median Timelines for Regulator and Applicant Per Year
























Median Time for Regulator Median Time for Applicant Total Median Approval Time 
improved efficiency and effectiveness of the whole
process. Both regulator and applicant were
compliant to the set timelines of 181 and 180 days,
respectively. The results of this study were different
from the study conducted in 2014 to evaluate central
registration procedure by the Gulf Cooperation
Council (Al-Rubaie et al,, 2014). The evaluation of
the Gulf Centralized Procedure indicated an increase
in median approval time from 107 calendar days in




         
       
        
      
        
       
          
       
      
        
         
        
      
          
       
      
    
      
       
     
      
      
        
      
       
      
       
      
      
      
       
         
       
         
      
       
        
      
      
       
      
       
         
         
        
        
      
         
        
      
       
      
          
        
          
       
      
       
          
       
         
          
        
        
      
        
          
       
         
    
        
         
         
       
        
      
     
          
          
       
       
       
        
        
    
        
          
       
         
       
        
       
 
               





a limited number of meetings by the Gulf Cooperation
Council-Drug Registration (GCC-DR), and a delay of
assessment reports due to a lack of standard
evaluation templates for product assessment, which
lead to an increase in correspondence by GCC-DR
to the sponsor requesting additional information. A
similar study conducted by Andrea et al. (2018) for a
regulatory review process in the South Africa
indicated overall regulatory median approval time
decreased by 14% in 2017 (1411 calendar days)
compared to 2016, despite the 27% increase in the
number of applications. The findings of South Africa
regulatory process further indicated the regulatory
agency had no target for overall approval time of new
active substance applications, no target for key
review milestones and an abridged assessment
procedure was not implemented.
Among the seven NMRAs implementing the EAC-
MRH program, only one (Tanzania Medicines and
Medical Devices Agency) granted marketing
authorisation to all 57 medicinal products
recommended for registration at EAC level.
Pharmacy and Poisons Board of the Republic of
Kenya granted marketing authorisation to 35
medicinal products and National Drug Authority of
Uganda granted marketing authorisation to 25
medicinal products, as indicated in Appendix 3.
Rwanda Food and Drugs Authority (Rwanda-FDA)
granted pre-registration to five antineoplastic drugs
and one antiseptic solution. Among the
antineoplastic drugs, four were approved at EAC
level on 3rd October 2015 and one in September
2016. The antiseptic solution was recommended for
registration at EAC level on 15th December 2017. In
addition, two medicinal products were awaiting
approval by Rwanda FDA which included an
antihypertensive drug and a drug for management of
overactive bladder. Both were recommended for
approval on 7th December 2018.
The Zanzibar Food and Drugs Agency (ZFDA)
granted pre-registration to an antiretroviral drug
which was recommended for approval in January
2018. The other NMRAs of the Republic of Burundi
and Republic of South Sudan had not registered any
medicinal products, as the applicants had not yet
shown interest in placing their products in these
countries’ markets by paying applicable fees. Non-
payment of fees by the applicants was also observed
for other countries (i.e. Uganda, Kenya and Rwanda)
as indicated in Appendix 3.
Once a regional recommendation was issued and
communicated to the applicant, the manufacturer
was required to pay the applicable fees for each of
the respective EAC Partner States NMRA for their
products to be placed in market. Each of the EAC
Partner States have fee guidance and structure
governed by that country’s regulations and
jurisdiction. Appendix 3 highlights the products in
which the applicant had not yet paid fees for their
products to be granted marketing authorisation (MA)
by the remaining six NMRAs. Most of the products
were granted MA by TMDA because it is the Lead
NMRA for the program component of drug evaluation
and registration. In this regard, TMDA received all
applications for joint evaluation procedure and
screened the dossier and distributes to assessors for
evaluation. Since it was the primary point for the joint
assessment procedure, most of the time, the
applicant submitted the dossier as per EAC CTD and
the applicable fee.
In order to encourage applicants to introduce their
products in all EAC Partner States markets, the 19th 
EAC Sectoral Council of Minister of Health, held on
1st November 2019, recommended a two year
window period for applicants to apply for marketing
authorization from all EAC NMRA directive
(EAC/SCHealth/19/Directive/050). In this regard, the
applicant had two years to pay the applicable fee in
each NMRA for their products to be placed in the
respective markets. In addition, the Council of
Ministers of Health further introduced a priority
voucher mechanism for applicants who made timely
payment of fees to all Partner States NMRAs
following positive outcome of EAC as per directive
EAC/SCHealth/19/Directive/053. Once a marketing
authorisation was granted by an individual NMRA, it
was valid for five years, as per EAC guideline for
registration of human medicinal products, and the
applicant was able to apply for renewal once the
validity expires using the same guidelines. However,
the applicant needed to specify in the application
form as “renewal” and not “new application.”
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The procedure recommended a period of 90 working
days for each of the NMRA to grant marketing
authorisation following a regional positive outcome
and payment of application fees by the applicant. The
median time for granting marketing authorisation for
three NMRA was analysed using an Excel sheet and
the findings indicated a decrease in total approval
median time from 174 working days in 2015 to 39
working days in 2019. The median time for PPB
ranged from 0-5 working days, NDA ranged from 150
-0 working days and TMDA ranged from 24- 5
working days (2015 to 2019). The reason for a long
median timeline of approval for NDA was the delay
for the applicant to pay the registration fee based on
national requirements.
For the period of 2019, the median time for PPB was
34 working days, NDA was zero working days and
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continuous improvements in the processes and high
compliance to agreed timelines for granting
marketing authorisation by NMRA.
EAC Joint GMP Inspection
Since commencement of EAC joint GMP inspections
in July 2015, the region conducted (22) joint
inspections of pharmaceutical manufacturing
facilities in Uganda, Bangladesh, India, Palestine,
Kenya, China, Germany, Italy, Belgium, Egypt,
Morocco and Tanzania. Among these, only one joint
inspection was triggered by a dossier application
submitted for joint review. The other inspections
were conducted based on the mapping of common
backlog of applications in all seven NMRA and upon
official request from the manufacturer.
Apart from steady progress in adhering to set
timelines for the joint review processes, EAC region
registered other key milestones in which some are
part of initial project targets (Appendix 1) and others
were part of program expansion phase. The key
milestones included:
a) Harmonization oftechnical guidelines
and procedures:
• EAC guideline for variations of registered
vaccines and pharmaceutical products
and similar biotherapeutic products;
• EAC procedure for Active Pharmaceutical
Ingredient Drug Master File (APIDMF);
• EAC procedure for recognition of GMP
decisions of other NMRA.
b) Regional institutions established and
strengthened:
• Establishment of two semi-autonomous
National Medicines Regulatory Authorities
(NMRA) (i.e. Zanzibar Food and Drugs
Agency [ZFDA] in 2017 and Rwanda Food
and Drugs Authority [Rwanda FDA];
• Four EAC NMRA were ISO 9001: 2015
certified namely Tanzania Medicines and
Medical Devices (TMDA), Zanzibar Food
and Drugs Agency (ZFDA), Pharmacy and
Poisons Board (PPB) and National Drug
Authority (NDA);
• One EAC NMRA attained the World Health
Organization (WHO) Maturity Level 3 (ML3)
i.e. Tanzania Medicines and Medical
Devices [TMDA].
c) Expansion of the program to include other
regulatory functions such as
Pharmacovigilance and Post Market
Surveillance System Strengthening; and
Clinical Trial Control Oversight with
adoption of the African Vaccine Regulatory
Forum (AVAREF) guidelines and tools for
domestication in the EAC region.
4. CHALLENGES
Despite progress made by the initiative, there were
some challenges identified by the study that should
be addressed to ensure improvement in the system
and optimize the processes to deliver the program
goal and objectives. The challenges observed by this
study are related to:
• Data Management: The study observed
incomplete data in the register of medicinal
products and the metric tool (registration).
This indicated limited consistency in data
entry to the metric tool when each step is
initiated and finalized at both national and
regional level. The metric tool was not
automated, which hinders accessibility and
timely entry of data by all NMRA and EAC
Secretariat. Based on the current
arrangement, the metric tool for registration
was managed by TMDA and GMP metric
tool was managed by NDA.
• Integrated Information Management
System: Lack of regional integrated
information management system (IMS) to
support sharing of dossiers and assessment
reports lead to a lag time.
• Capacity and Capabilities of EAC NMRA to
Conduct Scientific Review of Medicinal
Product Dossiers: limited capacity and
capability of some NMRA to conduct timely
scientific review of quality, safety and
efficacy data contribute to delay in
submission of assessment reports
• Quality of Dossiers Submitted by Applicants:
Low quality of dossier submissions by
applicants increase screening time due to
rounds of correspondence between Lead
NMRA and applicant.
• Submission of Queries by Applicants: Delay
in response to queries by applicants
contribute significantly to lengthy joint review
process
• Scientific Advice to Applicants: The initiative
did not provide scientific advice to applicants
to improve the quality of dossier submission
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• Regional Fee for Joint Regulatory Activities
and Central Mechanism for Collection of
Fee: The region did not yet establish
harmonized fee structure for joint regulatory
activities. Lack of regional fee and
mechanism for central collection of fee lead
to administrative burden to the applicant and
consequently limit the applicant to place their
products in the market of all EAC NMRA.
5. CONCLUSION
This study examined for the first time the joint
regulatory process timelines for the EAC-MRH
program. A clock-stop system was implemented,
which provides data to measure performance of the
system. However, the metric tools should be
consistently updated to ensure data completeness.
Automation of the metric tool is also key to ensure
easy accessibility and timely data entry by NMRA
and EAC Secretariat. Additionally, establishment of
EAC integrated information management system
would serve as a backup mechanism to track
timelines of the joint regulatory process.
The findings (2015-2019) demonstrate substantial
improvement in total median time for joint regulatory
review process (53 to 102 working days) and
marketing authorization by NMRAs (174 to 39
working days). This improvement indicates that the
EAC-MRH initiative has potential to continue to
improve regulatory efficiency in the region and
subsequently improves patient access to new,
innovative, safe, efficacious and quality medicines.
As EACregion moves towards implementation of
joint regulatory review process for variations,
biosimilars and Active Pharmaceutical Ingredient
Drug Master File (APIDMF) system, it is crucial to
establish strategic engagement and collaboration
with pharmaceutical industry stakeholders.
Additionally, there is a need to introduce a feedback
and scientific advice mechanism for pharmaceutical
industry stakeholders to improve future submissions.
Efforts should be made by the initiative to put a
regional fee structure and central fee collection
mechanism in place to reduce the administrative
burden to the applicants and ensure sustainability of
the EAC-MRH program.
..
5. RECOMMENDATIONS FOR NEXT STEPS
a) The EAC region should establish an
integrated information management system
(IMS) to facilitate timely sharing of dossiers
and assessment reports.
b) The EAC needs to automate EAC metric
tools to capture regulatory timelines and
ensure consistency in data entry.
c) The EAC should establish strategic
engagement and collaboration with industry
stakeholders and feedback mechanism to
address the quality of dossier to improve
future submissions and decrease frequency
of deficiency questions and, subsequently,
shorten the time required for joint review.
d) Industry stakeholders are encouraged to
take advantage of a two-year window period
following a positive regional
recommendation to place their products in all
Partner States market by payment of
applicable fees to all EAC NMRA. This will
facilitate availability of high-quality
medicines for the entire region.
e) EAC fee structure and a mechanism for
central collection of fees should be explored
to reduce administrative burden to
applicants.
f) EAC should strengthen less resourced
NMRA’s capacity on regulatory sciences to
ensure timely scientific review and
submission of assessment reports.
g) Conduct further research studies to :
• evaluate regulatory timelines for joint
GMP inspections;






     




        
     
    
     
        
       
       
     
      
     
  
 
          
      
     
    
    
 
          
      
      
    
     
  
          
    
      
     
 
        
     
 
      
     
     
   
     
     
      
     
    
    
    
       
   
      
      
     
       
       
       
   
   
 
          
      
     
    
        
         
     
       
    
    
         
         
    
  
     
         
       
      
   
   
       
    
     
    
 
      
       
      
    
  
      
    
    
        
      
    
        
      
  
      
      
    
        
      
      
    
       
  
            
      
      
17
• compare system performance efficiency
with other/similar international and
continental initiatives.
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 Table 1 
 EAC-MR  H P       rogramme Critical Milestones and Indicators of Success 
Objective  Critical Milestones   Indicators of Success 
   
1       EAC CTD implemented in at least             Eighteen (18) Medicines approved under joint assessment scheme by end of year 5 
       3 Partner States by end of year 3 
       and in all EAC Partner States by
   end of year 5 
2  A common integrated  IMS        NMRAs and 1 regional websites regularly updated
established and linked  in  all
        Centralized Portal to share information and work established Partner  States and EAC 
     Secretariat by end of year 4 
3  Quality  management system           Three (3) NMRAs ISO certified by the end of year 3 
     implemented in each of the EAC 
     Partner States NMRAs by end of 
 year 3 
4  Institutional, human  and Two  (2)  regional  centre’s  of  excellence  in  training  assessors    and GMP inspectors
    infrastructural capacity built by           established in the EAC region by the end of year 5 
   end of year 5 
         25 NMRAs and EAC Secretariat staff trained on project management 
 Regulatory  capacity  building
              24 assessors trained in assessment of quality, safety and efficacy of medicines by the end  programs  institutionalized  into
  of year 5  existing  structures  in  Partner
      States NMRAs by the end of year           24 inspectors trained on GMP inspection by end of year 5 
5 
   Regional capacity to  coordinate
 the  medicines  registration
harmonization strengthened  by
    the end of year 5 
5  Government  commitment  to           Rwanda and Burundi semi-autonomous NMRAs established by end of year 5 
    EAC-RH Programme secured by
        100 applications submitted to NMRAs as per EAC CTD    end of year 5 
      Partner States commitment to fund EAC-MRH programme    Industry-buy in and commitment 
   to EAC-MRH program secured 
     by the end of year 5 
 Public  awareness on EAC-RH 
     created by end of year 5 
6  A  framework for mutual             Seven (7) NMRAs recognizing regulatory decisions made by other NMRAs based on
 recognition  of  regulatory        mutual recognition framework by end of year 5 
 decisions made  by  other EAC 
   Partner States NMRAs developed 










   
  
             
 




      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      




Summary of Product Registration Timelines (Submission to End of Assessment) for Regulator and Applicant 
Product Number Year Product Category Type of Assessment Regulator Applicant
Timelines Timelines
001 2015 Antineoplastic Abridged 53 0
002 2015 Antineoplastic Abridged 53 0
003 2015 Antineoplastic Abridged 53 0
004 2015 Antineoplastic Abridged 53 0
005 2015 Antihypertensive Full 125 927
006 2015 Antihypertensive Full 125 927
007 2015 Antihypertensive Full 125 927
008 2016 Antineoplastic - 96 30
009 2016 Antineoplastic - - -
010 2016 Antidiabetic Full 327 419
011 2016 Antidiabetic Full 327 419
012 2016 Antihypertensive Full 327 419
013 2016 Antihypertensive Full 327 419
014 2016 Antituberculosis Abridged 141 27
015 2016 Antihypertensive - 289 141
016 2016 Antihypertensive - 289 141
017 2016 Antihypertensive - 289 141
018 2016 Antineoplastic - 391 294




      
      
      
      
      
      
      
      
      
   
 
   
      
      
      
      
      
      
      
   
 
   
   
 
   
      
      
      
      
  
 
   
  
 







2016 - - - -
021 2016 Antihypertensive - 266 380
022 2016 Antihypertensive - 266 380
023 2016 Antineoplastic - 153 42
024 2016 Antipyretic - 267 194
2016 Antiseptic - 343 180
026 2016 Antibiotic - 104 65
027 2017 Antifungal - 169 119
028 2017 Antifungal - 169 119
029 2017 Mineral - 381 43Supplements
2017 Antiseptic - 180 412
031 2017 Antineoplastic - 207 95
032 2017 Antineoplastic - 135 0
033 2017 Antineoplastic - 135 0
034 2017 Antiretrovirals - 101 254
2017 Antiallergics - 122 88
036 2018 Antineoplastic Abridged 73 9
037 2018 Overactive - 174 47Bladder
038 2018 Overactive - 174 47Bladder
039 2018 Antibiotic Abridged 87 74
2018 Antiretroviral Full 166 35
041 2019 Antineoplastic Full 63 0
042 2019 Antineoplastic Full 63 0
043 2019 Antineoplastic/Bio Full 85 0logical




   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
      
      
   
  
   





    
 
   
     
 
   
     
 
   
     
 































050 2019 Antivertigo Full 44 0
051 2019 Antineoplastic Abridged 85 0
052 2019 Emergence Full - -Allergic Reaction
053 2019 Nerve Agent & Full
Insecticide - -
Poisoning
054 2019 Treatment of Full - -Asthma
055 2019 Treatment of Male
Impotence
Full 102 51
056 2019 Treatment of Male
Impotence
Full 102 51







   












         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         




Registration Timelines at National Level (Marketing Authorisation) for Each EAC National Medicines Regulatory Authorities
Product Year
Number
Marketing Authorisation Timelines (Working Days)
PPB NDA TM Rwan DPL ZFDA DFC 
DA da M A
FDA
001 2015 0 150 0 PR NS NS NS
002 2015 0 150 30 PR NS NS NS
003 2015 0 150 0 PR NS NS NS
004 2015 0 150 30 PR NS NS NS
005 2015 NS 43 24 NS NS NS NS
006 2015 NS 43 24 NS NS NS NS
007 2015 NS 43 24 NS NS NS NS
008 2016 0 594 307 PR NS NS NS
009 2016 0 47 1 NS NS NS NS
010 2016 0 1 53 NS NS NS NS
011 2016 0 1 53 NS NS NS NS
012 2016 0 NS 53 NS NS NS NS
013 2016 0 NS 53 NS NS NS NS
014 2016 ND NS 272 PR NS NS NS
015 2016 0 NS 53 NS NS NS NS
016 2016 0 NS 53 WA NS NS NS
017 2016 0 0 53 NS NS NS NS
018 2016 ND 0 53 NS NS NS NS
019 2016 0 NS 25 NS NS NS NS




         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         





























2016 0 0 53 NS NS NS NS
2016 0 0 53 NS NS NS NS
2016 ND 340 108 NS NS NS NS
2016 0 0 0 NS NS NS NS
2016 0 NS 40 NS NS NS NS
2016 0 498 83 NS NS NS NS
2017 0 NS 49 NS NS NS NS
2017 0 NS 49 NS NS NS NS
2017 0 NS 40 NS NS NS NS
2017 ND NS 33 NS NS NS NS
2017 0 0 48 PR NS NS NS
2017 0 116 49 NS NS NS NS
2017 0 116 49 NS NS NS NS
2017 ND 0 27 NS NS NS NS
2017 ND NS 70 NS NS PR NS
2018 51 NS 48 NS NS NS NS
2018 51 NS 48 NS NS NS NS
2018 ND 0* 1 WA NS NS NS
2018 128 NS 27 NS NS NS NS
2018 ND NS 79 NS NS NS NS
2019 ND NS 155 NS NS NS NS
2019 ND NS 5 NS NS NS NS
2019 ND NS 5 NS NS NS NS
2019 0 NS 79 NS NS NS NS
2019 NS NS 5 NS NS NS NS
2019 NS NS 5 NS NS NS NS




         
         
         
         
         
         
         
         
         
         
 
 
    
         
       
           
          
          
          
           
       
         
   
      
             
             
  
25
048 2019 34 NS 0* NS NS NS NS
049 2019 34 0 0* NS NS NS NS
050 2019 34 0 0* NS NS NS NS
051 2019 ND NS 40 NS NS NS NS
052 2019 ND NS 40 NS NS NS NS
053 2019 ND NS 40 NS NS NS NS
054 2019 ND NS 40 NS NS NS NS
055 2019 ND NS 5 NS NS NS NS
056 2019 ND NS 5 NS NS NS NS
057 2019 0 WA 5 NS NS NS NS
Key to Appendix 3
PPB- Pharmacy and Poisons Board, Republic of Kenya
NDA- National Drug Authority, Republic of Uganda
TMDA- Tanzania Medicines and Medical Devices Authority, United Republic of Tanzania
Rwanda FDA- Rwanda Food and Drugs Authority, Republic of Rwanda
DPML- Department of Pharmaceuticals and Medical Laboratories, Republic of Burundi
ZFDA- Zanzibar Food and Drugs Agency, United Republic of Tanzania
DFCA – Drug and Food Control Authority, Republic of South Sudan
PR- Pre-registration pending fee payment by applicant
NS- Application for marketing authorisation not submitted by applicant
ND- No Data
WA – Submitted waiting NMRA approval
Zero (0) Days- Product already registered in country before EAC joint assessment
0* Days - Product registered between 5 to 30 days before regional recommendation
